Sugi Predict

Sugi Predict / Compounds / SCHEMBL1425575

SCHEMBL1425575

SCHEMBL1425575

CC(C)(C)OC(=O)N1CC2CC=CCC2C1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.58
▸ USP2 O75604 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ GPR119 Q8TDV5 4/20 0.43
▸ PREP P48147 1/20 0.43
▸ NAMPT P43490 1/20 0.42
▸ HPGD P15428 1/20 0.41
▸ RORC P51449 1/20 0.41
▸ LIPE Q05469 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ JAK2 O60674 1/20 0.40
▸ JAK1 P23458 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1425576 1.00 NR1H2 (0.58) NR1H2USP2SMN1; SMN2GPR119PREP
SCHEMBL30954888 0.85 NR1H2 (0.51) NR1H2USP2SMN1; SMN2GPR119PREP
SCHEMBL25010845 0.82 NR1H2 (0.74) NR1H2USP2SMN1; SMN2GPR119PREP
SCHEMBL10242790 0.82 NR1H2 (0.74) NR1H2USP2SMN1; SMN2GPR119PREP
SCHEMBL23906106 0.82 NR1H2 (0.64) NR1H2USP2SMN1; SMN2GPR119PREP
SCHEMBL19456156 0.82 NR1H2 (0.74) NR1H2USP2SMN1; SMN2GPR119PREP
SCHEMBL4224986 0.82 NR1H2 (0.74) NR1H2USP2SMN1; SMN2GPR119PREP
SCHEMBL23963745 0.79 NR1H2 (0.60) NR1H2USP2SMN1; SMN2GPR119PREP
SCHEMBL8256164 0.79 NR1H2 (0.60) NR1H2USP2SMN1; SMN2GPR119PREP
SCHEMBL24693307 0.79 NR1H2 (0.60) NR1H2USP2SMN1; SMN2GPR119NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025052278-A1 PYRROLIDINE BASED CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS GENEVANT SCIENCES GMBH (CH) 2025-03-13 — — WO disclosed
WO-2025049419-A1 PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORS GENZYME CORPORATION (US) 2025-03-06 — — WO disclosed
CN-118234707-A Cyclic lipids and methods of use thereof 雷纳嘉德医疗管理公司 2024-06-21 — — CN disclosed
WO-2024028795-A1 HETEROBICYCLIC COMPOUNDS AS ORAL GLP1R AGONISTS ZYDUS LIFESCIENCES LIMITED (IN) 2024-02-08 — — WO disclosed
US-11773061-B2 Cyclic lipids and methods of use thereof RENAGADE THERAPEUTICS MANAGEMENT INC. (US) 2023-10-03 — — US disclosed
US-11773061-B2 Cyclic lipids and methods of use thereof RENAGADE THERAPEUTICS MANAGEMENT INC. (US) 2023-10-03 — — US disclosed
US-20230202977-A1 CYCLIC LIPIDS AND METHODS OF USE THEREOF RENAGADE THERAPEUTICS MANAGEMENT INC. 2023-06-29 — — US disclosed
US-20230202977-A1 CYCLIC LIPIDS AND METHODS OF USE THEREOF RENAGADE THERAPEUTICS MANAGEMENT INC. 2023-06-29 — — US disclosed
EP-3347097-B1 SUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF THE KINASES JAK, FLT3 AND AURORA SUNSHINE LAKE PHARMA CO LTD (CN) 2021-02-24 — — EP disclosed
EP-3312164-B1 SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE CALITOR SCIENCES LLC (US) 2020-12-09 — — EP disclosed
WO-2015148867-A1 SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE CALITOR SCIENCES, LLC (US) 2015-10-01 — — WO disclosed
US-20150274704-A1 SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-10-01 — — US disclosed
US-20150274705-A1 SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-10-01 — — US disclosed
US-8987442-B2 Deuterium-substituted xanthine derivatives and methods of use CONCERT PHARMACEUTICALS, INC. (US) 2015-03-24 — — US disclosed
WO-2013138210-A1 SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF USE XI NING (US) 2013-09-19 — — WO disclosed
US-8481524-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-09 — — US disclosed
US-20110136789-A1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-09 — — US disclosed
EP-2205589-B1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMA (US) 2011-03-23 — — EP disclosed
EP-2205589-A2 C-MET PROTEIN KINASE INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2010-07-14 — — EP disclosed
WO-2009045992-A2 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-04-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136789-A1 C-MET PROTEIN KINASE INHIBITORS MET, PRKCH, ABL1 NR1H2 2477/4885USP2 2356/4885SMN1; SMN2 3535/4885
US-20150274705-A1 SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE PRKACA, PACSIN2, PRKDC NR1H2 1076/4885USP2 1871/4885SMN1; SMN2 703/4885
US-11773061-B2 Cyclic lipids and methods of use thereof SGMS1, SGMS2, LNPEP NR1H2 566/4885USP2 2359/4885SMN1; SMN2 2719/4885
US-20230202977-A1 CYCLIC LIPIDS AND METHODS OF USE THEREOF SGMS1, SGMS2, LNPEP NR1H2 566/4885USP2 2359/4885SMN1; SMN2 2719/4885
US-20150274704-A1 SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE PRKACA, PRKDC, PRKACB NR1H2 976/4885USP2 1765/4885SMN1; SMN2 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.